Immunotherapy Shows Doubled Median Survival Time for Advanced Lung Cancer Patients

Shirish Gadgeel, MBBS, reviews the continued positive findings from a clinical trial that combines pembrolizumab with chemotherapy to treat metastatic non-small cell lung cancer.